Listing Regulation – Alligator Bioscience

2026-05-05

Regulatory

Alligator Bioscience AB reports financial results for the period 1 January – 31 March 2026 and provides a business update

Mitazalimab momentum: Final OPTIMIZE‑1 outcomes were presented at ASCO GI 2026, with additional investigator‑initiated data acce ...

2026-03-30

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2026-03-27

Regulatory

The Nomination Committee of Alligator Bioscience AB (publ) (“Alligator Bioscience”) proposes re-election of Hans-Peter Ostler an ...

2026-03-20

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...

2026-03-16

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2026-02-27

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2026-02-12

Regulatory

Rights issue completed: Approximately SEK 91 million (gross) raised in December, strengthening financial position with additional warrant up ...

2026-01-07

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-12-22

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...